Literature DB >> 24075514

GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion.

Yongchao Yang1, Xiao Yu, Lihua Huang, Can Yu.   

Abstract

OBJECTIVE: To explore the mechanism of GLP-1R agonist-induced rat pancreatic tissue lesion.
METHODS: Thirty SD male rats were divided into three groups, namely GLP-1R agonist experimental group, diabetes-model experimental group and control group. Diabetes-model rats were induced by streptozotocin and high-sugar high-fat diet. GLP-1R agonist group and diabetes-model group were administered with GLP-1R agonist in dose 5 μg/kg each time, twice a day. After 10 weeks of treatment, the amount of matrix metalloproteinase (MMP)-2 and MMP-9, and expression of α-smooth muscle actin (α-SMA) and type III collagen protein in pancreatic tissue were measured.
RESULTS: The amount of MMP-2 and MMP-9 in GLP-1R agonist group and diabetes-model group were significantly higher than the control group. Compared with the GLP-1R agonist group, the diabetic model group had more severe pathological changes of pancreatic tissue interstitial edema, inflammatory cell infiltration, glandular atrophy and fibrosis, and significantly increased pancreatic tissue MMP-2 and MMP-9 levels, significantly increased α-SMA and collagen III-positive cell counts, all the differences were statistically significant. α-SMA and type III collagen were expressed in all parts of the lesions of GLP-1R agonist group and diabetes-model group. α-SMA can only be observed in the vessel wall in control group, however, in the other two groups, α-SMA can also be observed in pancreatic acinar cell interstitia, in addition to vessel wall.
CONCLUSIONS: Long-term subcutaneous GLP-1R agonist injection may activate pancreatic stellate cells, causing the expression of α-SMA and collagen III and the amount of MMP-2 and MMP-9 in pancreatic acinar cell interstitial significantly increasing, and thus inducing chronic inflammatory change.
Copyright © 2013 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GLP-1R agonist; Histopathology; Pancreatic stellate cell

Mesh:

Substances:

Year:  2013        PMID: 24075514     DOI: 10.1016/j.pan.2013.07.281

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  5 in total

Review 1.  Pancreatic stellate cells - rising stars in pancreatic pathologies.

Authors:  P Hrabák; M Kalousová; T Krechler; T Zima
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

2.  Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy.

Authors:  M Pilar Valdecantos; Laura Ruiz; Virginia Pardo; Luis Castro-Sanchez; Carmelo García-Monzón; Borja Lanzón; Javier Rupérez; Coral Barbas; Jaqueline Naylor; James L Trevaskis; Joseph Grimsby; Cristina M Rondinone; Ángela M Valverde
Journal:  Sci Rep       Date:  2018-11-07       Impact factor: 4.379

Review 3.  Pathological Mechanisms in Diabetes of the Exocrine Pancreas: What's Known and What's to Know.

Authors:  Qiong Wei; Liang Qi; Hao Lin; Dechen Liu; Xiangyun Zhu; Yu Dai; Richard T Waldron; Aurelia Lugea; Mark O Goodarzi; Stephen J Pandol; Ling Li
Journal:  Front Physiol       Date:  2020-10-28       Impact factor: 4.566

4.  Regulation of Pancreatic Fibrosis by Acinar Cell-Derived Exosomal miR-130a-3p via Targeting of Stellate Cell PPAR-γ.

Authors:  Qiang Wang; Hao Wang; Qingxu Jing; Yang Yang; Dongbo Xue; Chenjun Hao; Weihui Zhang
Journal:  J Inflamm Res       Date:  2021-02-24

5.  The Use of Values WNR and GNR to Distinguish between and Diagnose Different Types of Pancreatitis.

Authors:  Liwen Luo; Junfeng Zhang; Jiali Yang; Hongyu Zhang; Yichen Tang; Di Yang; Hui Dong; Yuzhang Wu; Huaizhi Wang; Bing Ni; Zhiqiang Tian
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-22       Impact factor: 6.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.